Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention Report

Exclusively available on Available only on IvyPanda® Made by Human No AI

Causative Agent

The World Health Organization notes that acute respiratory illness known as influenza has afflicted human beings from ancient civilizations to date (Gerdil, 2003). Swine flu is a strain of influenza A viruses in the family Orthomyxoviridae (OIE, 2009). This strain is most commonly found in pigs. Influenza A viruses are further characterized by subtypes, a relatively stable subtype of which is the H1N1 virus. H1N1 is the etiologic agent of most swine influenza and for this reason, this is the strain most commonly associated with “classical swine influenza”.

Swine Flu was first proposed to be related to human influenza during the 1918 flu pandemic which resulted in the subsequent death of 40-50 million people throughout the world (Zimmer & Burke, 2009). During this pandemic, pigs became sick at the same time as humans, therefore, leading to an investigation as to the relationship. Smith Andrewes identified a virus as being the causative agent for influenza. H1N1 viruses are readily transmitted and a host will begin excreting swine influenza viruses within 24 hours of infection and the shedding will go on for up to 7 to 10 days post-infection (OIE, 2009). The World Health Organization (2009) reveals that novel influenza A(H1N1) which appeared in 2009 is spread in the same manner as seasonal flu and can survive for up to 3 hours outside of a host in dry mucus.

Populations Affected

The World Health Organization reported that as of February this year, 213 countries had reported laboratory-confirmed cases of the H1N1 virus in their territories (Reuters, 2010). Reports by CDC (2009) show that H1N1 flu fatalities were highest in the 25 to 49 age bracket which accounted for 39% of the deaths by H1N1. The second age group most affected by H1N1 was the 50 to 64 age bracket which accounted for 25% of the fatalities. Young people aged 5 to 24 were reported to be the third most susceptible accounting for 16% of the affected. This preferential infection of younger people by swine flu is a significant difference of the virus from the seasonal flu which causes fatalities mostly in the older population (65 years and over).

The World Health Organization has identified the following individuals as being at greater risk from the virus: pregnant women, children under the age of 5, chronic disease sufferers, and patients with immunosuppression (WHO, 2009). These are the people most likely to exhibit severe manifestations of the H1N1 virus. Owing to the classification of these groups as being high risk, it was recommended that they be given priority in vaccination when the vaccine was first made available.

A course of the Disease

Novel H1N1 is contagious from the first day before symptoms appear through to 7 days after the symptoms appear. The virus is shed in nasal secretions of the infected party and is disseminated through droplets or sneezing. According to the World Health organization, most people who have contracted the H1N1 virus experience influenza-like symptoms which include; sudden-onset high fever, sore throat, cough, runny nose, fever, malaise, headache and joint muscle. 25% of the infected people may also experience nausea, vomiting and diarrhea. The virus may result in respiratory tract disease which may result in the respiratory failure of the victim. Pregnant women and people with underlying chronic medical conditions such as asthma and chronic lung disease are most susceptible to this deadly manifestation of the virus.

Reuters (2010) notes that the CDC has developed a polymerase chain reaction diagnostic test kit to help in the detection of the novel H1N1 virus. These test kits were meant to increase the testing capacity of nations in the event of an increase in reported cases of infections.

Intervention

The new strain of the H1N1 virus experienced in the 2009 pandemic was different from other strains of the disease and older antiviral drugs were ineffective against the virus. The World Health Organization (2009) earmarked two antiviral drugs; oseltamivir and zanamivir as having the ability to treat novel H1N1 infections. The drugs stop the virus from multiplying by blocking the action of neuraminidase, the HIN1 Protein. The drugs have been observed to be effective in reducing both the duration of the illness and the severity of the symptoms.

As of early 2009, there was no available vaccine against the novel H1N1 virus and the available seasonal influenza vaccines offered no protection against H1N1. Owing to the danger posed by the virus, companies undertook thorough research to come up with a vaccine and as of late 2009, a vaccine was available. The Center for Disease Control and Prevention recommended that every person be vaccinated to protect against the novel H1N1 virus although the high-risk groups were to be given priority (CDC, 2010). While vaccines contain dead viruses as part of their mark-up, they cannot cause the disease although they can result in flu-like symptoms which are generally milder and last for shorter durations.

Prevention-wise, exercising person hygiene is key to protection against the virus. This is because H1N1 is spread through coughing and sneezing by infected people or by touching surfaces that contain the virus. Washing of hands is therefore especially important to avoid infection spread through touching surfaces contaminated with the flu virus.

References

Center for Disease Control and Prevention (2010). . Web.

Gerdil, C. (2003). The Annual Production Cycle for Influenza Vaccine. Elsevier.

OIE. (2009). Swine Influenza Technical Disease Card. Web.

Reuters, T. Influenza A (H1N1) Disease Briefing From Thomson Reuters Integrity. Prous Science Integrity.

Salaam-Blyther, T. (2009). 2009 Influenza Pandemic: U. S. Responses to Global Human Cases. Diane Publishing.

WHO (2009). What you need to know about novel influenza A(H1N1). Web.

Zimmer, S. M. & Burke, S. D. (2009). Historical Perspective – Emergence of Influenza A (H1N1) Viruses. New England Journal of Medicine. 361: 279-285.

More related papers Related Essay Examples
Cite This paper
You're welcome to use this sample in your assignment. Be sure to cite it correctly

Reference

IvyPanda. (2022, March 19). Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention. https://ivypanda.com/essays/swine-flu-h1n1-populations-affected-course-of-the-disease-intervention/

Work Cited

"Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention." IvyPanda, 19 Mar. 2022, ivypanda.com/essays/swine-flu-h1n1-populations-affected-course-of-the-disease-intervention/.

References

IvyPanda. (2022) 'Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention'. 19 March.

References

IvyPanda. 2022. "Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention." March 19, 2022. https://ivypanda.com/essays/swine-flu-h1n1-populations-affected-course-of-the-disease-intervention/.

1. IvyPanda. "Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention." March 19, 2022. https://ivypanda.com/essays/swine-flu-h1n1-populations-affected-course-of-the-disease-intervention/.


Bibliography


IvyPanda. "Swine Flu H1N1: Populations Affected, Course of the Disease, Intervention." March 19, 2022. https://ivypanda.com/essays/swine-flu-h1n1-populations-affected-course-of-the-disease-intervention/.

If, for any reason, you believe that this content should not be published on our website, please request its removal.
Updated:
This academic paper example has been carefully picked, checked and refined by our editorial team.
No AI was involved: only quilified experts contributed.
You are free to use it for the following purposes:
  • To find inspiration for your paper and overcome writer’s block
  • As a source of information (ensure proper referencing)
  • As a template for you assignment
Privacy Settings

IvyPanda uses cookies and similar technologies to enhance your experience, enabling functionalities such as:

  • Basic site functions
  • Ensuring secure, safe transactions
  • Secure account login
  • Remembering account, browser, and regional preferences
  • Remembering privacy and security settings
  • Analyzing site traffic and usage
  • Personalized search, content, and recommendations
  • Displaying relevant, targeted ads on and off IvyPanda

Please refer to IvyPanda's Cookies Policy and Privacy Policy for detailed information.

Required Cookies & Technologies
Always active

Certain technologies we use are essential for critical functions such as security and site integrity, account authentication, security and privacy preferences, internal site usage and maintenance data, and ensuring the site operates correctly for browsing and transactions.

Site Customization

Cookies and similar technologies are used to enhance your experience by:

  • Remembering general and regional preferences
  • Personalizing content, search, recommendations, and offers

Some functions, such as personalized recommendations, account preferences, or localization, may not work correctly without these technologies. For more details, please refer to IvyPanda's Cookies Policy.

Personalized Advertising

To enable personalized advertising (such as interest-based ads), we may share your data with our marketing and advertising partners using cookies and other technologies. These partners may have their own information collected about you. Turning off the personalized advertising setting won't stop you from seeing IvyPanda ads, but it may make the ads you see less relevant or more repetitive.

Personalized advertising may be considered a "sale" or "sharing" of the information under California and other state privacy laws, and you may have the right to opt out. Turning off personalized advertising allows you to exercise your right to opt out. Learn more in IvyPanda's Cookies Policy and Privacy Policy.

1 / 1